Skip to main navigation Skip to search Skip to main content

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

  • Charles J. Ryan
  • , Matthew R. Smith
  • , Karim Fizazi
  • , Fred Saad
  • , Peter F. A. Mulders
  • , Cora N. Sternberg
  • , Kurt Miller
  • , Christopher J. Logothetis
  • , Neal D. Shore
  • , Eric J. Small
  • , Joan Carles. Joan
  • , Thomas W. Flaig
  • , Mary-Ellen Taplin
  • , Celestia S. Higano
  • , Paul de Souza
  • , Johann S. de Bono
  • , Thomas W. Griffin
  • , Peter de Porre
  • , Margaret K. Yu
  • , Youn C. Park

Research output: Contribution to journalArticlepeer-review

1256 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science